Swedish Orphan Biovitrum's co-promotion rights for Mimpara® sold back to Amgen


                        
Stockholm, Sweden - November 5, 2010 - Swedish Orphan Biovitrum (STO: SOBI)
today announced a mutual agreement with Amgen whereby  Swedish Orphan Biovitrum
will sell back its co-promotion rights in the Nordic countries for Mimpara®
(cinacalcet) to Amgen (NASDAQ: AMGN) for strategic business reasons. Swedish
Orphan Biovitrum will receive an undisclosed payment from Amgen for these rights
upfront.

"We have appreciated the long and successful Mimpara partnership with Amgen. We
are grateful that they will continue to provide this valuable product to
patients in need in the Nordic countries. Swedish Orphan Biovitrum resources
that have supported the product will be used to fill resource gaps for products
that are moving into the launch phase such as Yondelis, Multiferon and
Ruconest." said Kennet Rooth, Head of Marketing and Sales at Swedish Orphan
Biovitrum.



About Mimpara® (cinacalcet)
Mimpara is a specialist care product indicated for the treatment of secondary
hyperparathyroidism in patients with chronic kidney disease on dialysis. The
product is also indicated for the treatment of hypercalcemia in patients with
parathyroid carcinoma, as well as for managing hypercalcemia in patients with
primary hyperparathyroidism, when surgery not is an option. These rights were
granted to Biovitrum in 2003 as part of the 11betaHSD out-licensing deal with
Amgen. Swedish Orphan Biovitrum has co-promoted Mimpara together with Amgen in
the Nordic region since its launch in 2005. Swedish Orphan Biovitrum's co-
promotion revenues for Mimpara were in 2009 26.2 MSEK.



About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and
inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues
2009e of about 2 BSEK and approximately 500 employees. The head office is
located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
For more information please visitwww.sobi.com.



For more information please contact: Swedish Orphan Biovitrum AB (publ):
Kennet Rooth, VP Marketing and Sales
Phone. +46 8 6972330


Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mailerik.kinnman@sobi.com



Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on November 5, 2010 at 8:00 a.m. CET.







Subscribe

Documents & Links